Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden; Department of Protein Science, KTH - Royal Institute of Technology, Stockholm, Sweden.
Translational Science, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Mol Cell Proteomics. 2019 Dec;18(12):2433-2446. doi: 10.1074/mcp.RA119.001765. Epub 2019 Oct 7.
Stable isotope-labeled standard (SIS) peptides are used as internal standards in targeted proteomics to provide robust protein quantification, which is required in clinical settings. However, SIS peptides are typically added post trypsin digestion and, as the digestion efficiency can vary significantly between peptides within a protein, the accuracy and precision of the assay may be compromised. These drawbacks can be remedied by a new class of internal standards introduced by the Human Protein Atlas project, which are based on SIS recombinant protein fragments called SIS PrESTs. SIS PrESTs are added initially to the sample and SIS peptides are released on trypsin digestion. The SIS PrEST technology is promising for absolute quantification of protein biomarkers but has not previously been evaluated in a clinical setting. An automated and scalable solid phase extraction workflow for desalting and enrichment of plasma digests was established enabling simultaneous preparation of up to 96 samples. Robust high-precision quantification of 13 apolipoproteins was achieved using a novel multiplex SIS PrEST-based LC-SRM/MS Tier 2 assay in non-depleted human plasma. The assay exhibited inter-day coefficients of variation between 1.5% and 14.5% (median = 3.5%) and was subsequently used to investigate the effects of omega-3 carboxylic acids (OM3-CA) and fenofibrate on these 13 apolipoproteins in human plasma samples from a randomized placebo-controlled trial, EFFECT I (NCT02354976). No significant changes were observed in the OM3-CA arm, whereas treatment with fenofibrate significantly increased apoAII and reduced apoB, apoCI, apoE and apoCIV levels. The reduction in apoCIV following fenofibrate treatment is a novel finding. The study demonstrates that SIS PrESTs can facilitate the generation of robust multiplexed biomarker Tier 2 assays for absolute quantification of proteins in clinical studies.
稳定同位素标记的标准(SIS)肽被用作靶向蛋白质组学中的内标,以提供稳健的蛋白质定量,这在临床环境中是必需的。然而,SIS 肽通常是在胰蛋白酶消化后添加的,并且由于蛋白质内的肽之间的消化效率可能有很大差异,因此测定的准确性和精密度可能会受到影响。这些缺点可以通过人类蛋白质图谱项目引入的一类新的内标来补救,这些内标基于称为 SIS PrEST 的 SIS 重组蛋白片段。SIS PrEST 最初添加到样品中,然后在胰蛋白酶消化时释放 SIS 肽。SIS PrEST 技术有望用于蛋白质生物标志物的绝对定量,但尚未在临床环境中进行评估。建立了一种自动化和可扩展的固相萃取工作流程,用于脱盐和富集血浆消化物,从而能够同时制备多达 96 个样品。使用新型基于 SIS PrEST 的 LC-SRM/MS 二级联测定法,对非耗尽的人血浆中的 13 种载脂蛋白进行了稳健的高精度定量。该测定法的日内变异系数在 1.5%至 14.5%之间(中位数为 3.5%),随后用于研究随机安慰剂对照试验 EFFECT I(NCT02354976)中,ω-3 羧酸(OM3-CA)和非诺贝特对这些 13 种载脂蛋白在人血浆样本中的影响。在 OM3-CA 组中未观察到显著变化,而用非诺贝特治疗可显著增加载脂蛋白 AII 并降低载脂蛋白 B、CI、E 和 CIV 水平。非诺贝特治疗后载脂蛋白 CIV 减少是一个新发现。该研究表明,SIS PrEST 可以促进用于临床研究中蛋白质绝对定量的稳健的多重生物标志物二级联测定法的生成。